Advances in the development of anticancer drugs have decreased mortality rates for many cancers and increased patient survival. However, concerns have been raised about possible long-term effects of these new anticancer agents, such as cardiovascular toxicity. Alexandre Durand-Salmon and Joe-Elie Salem at Banook Group show why assessing cardiac safety is imperative in drug development.